|1.||Azevedo, Ruben: 1 article (01/2008)|
|2.||Wendel, Hans Peter: 1 article (01/2008)|
|3.||Ziemer, Gerhard: 1 article (01/2008)|
|4.||Dietz, Klaus: 1 article (01/2008)|
|5.||Schiebold, Daniela: 1 article (01/2008)|
|6.||Straub, Andreas: 1 article (01/2008)|
|7.||Yamaguchi, Syohjiro: 1 article (08/2004)|
|8.||Tabata, Shigeki: 1 article (08/2004)|
|9.||Arai, Sadahiko: 1 article (08/2004)|
|10.||Tomita, Shigeyuki: 1 article (08/2004)|
02/15/1996 - "Thus, FK633 is a specific GPIIb/IIIa antagonist with potent anti-thrombotic effect in vivo, but careful dosing study might be necessary to avoid the bleeding complications in the clinic."
08/01/2004 - "An ultra-short acting glycoprotein IIb/IIIa antagonist, FK633, is effective in preventing both platelet aggregation and thrombocytopenia during CPB, and may be effective for minimizing postoperative bleeding."
02/01/1998 - "Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model."
03/01/1997 - "Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery."
02/15/1996 - "In dogs, bolus injection of FK633 at 0.1 mg/kg significantly suppressed ex vivo ADP-induced platelet aggregation (>40% inhibition) and thrombus formation at stenosed and injured coronary artery, but did not prolong template bleeding time. "
02/01/1998 - "Pretreatment with 0.32 mg/kg i.v. of FK633 significantly prevented occlusive thrombus formation, but aspirin at 10 mg/kg i.v. did not. "
|5.||Vascular System Injuries
|2.||Dihydrotachysterol (AT 10)
|3.||Aspirin (Acetylsalicylic Acid)
|4.||Adenosine Diphosphate (ADP)